Skip to main content

POINT Biopharma Global, Inc. (PNT)

NASDAQ: PNT · IEX Real-Time Price · USD
7.97 -0.04 (-0.50%)
Oct 15, 2021 4:00 PM EDT - Market closed
Market Cap718.27M
Revenue (ttm)n/a
Net Income (ttm)-27.94M
Shares Out57.58M
EPS (ttm)-0.83
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume66,079
Open8.09
Previous Close8.01
Day's Range7.68 - 8.09
52-Week Range6.64 - 18.08
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 12, 2021

About PNT

POINT Biopharma Global Inc., a late-stage clinical precision oncology company, focuses on the development and commercialization of radiopharmaceuticals for the treatment of cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, ...

IndustryBiotechnology
Founded2019
CountryUnited States
Stock ExchangeNASDAQ
Ticker SymbolPNT
Full Company Profile

News

ARTMS Inc. Announces Health Canada Submission for Ga-68 Production and Tri-party Collaboration to Advance Ga-68 Imagi...

BURNABY, British Columbia--(BUSINESS WIRE)--ARTMS Inc. (ARTMS), the global leader in developing and commercializing novel products enabling cyclotron production of the world's most needed medical radioi...

3 days ago - Business Wire

POINT Biopharma Posts New Preclinical Data, Exercises Option For FAP Inhibitor

Point Biopharma Global Inc (NASDAQ: PNT) has additional preclinical data from its fibroblast activation protein-alpha (FAP-alpha) inhibitor program, PNT2004.  The new data demonstrate rapid and persiste...

2 weeks ago - Benzinga

POINT Biopharma Releases New Data and Exercises Option for Best-in-Class FAP Inhibitor

Unique FAP targeting warhead combined with Actinium-225 or Lutetium-177 demonstrated complete tumor regression and long-term survival in preclinical models

2 weeks ago - GlobeNewsWire

NorthStar Medical Radioisotopes and POINT Biopharma Announce Supply Agreement for Therapeutic Medical Radioisotope Ac...

BELOIT, Wis. & INDIANAPOLIS--(BUSINESS WIRE)--NorthStar Medical Radioisotopes and POINT Biopharma have signed a supply agreement for the therapeutic medical radioisotope actinium-225 (Ac-225).

1 month ago - Business Wire

POINT Biopharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

INDIANAPOLIS, Sept. 07, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life changin...

1 month ago - GlobeNewsWire

POINT Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Update

Strengthened the Company's balance sheet by completing the business combination with Therapeutics Acquisition Corp (“RACA”), with gross proceeds from the transaction totaling approximately $286.7 million

2 months ago - GlobeNewsWire

POINT Biopharma Debuts as Publicly Traded Next-Generation Radiotherapeutics Company

Common stock to commence trading on the Nasdaq Capital Market on July 1, 2021 under the ticker symbol “PNT”

3 months ago - GlobeNewsWire

Research Alliance Corp. I Announces Effectiveness of Registration Statement for Proposed Business Combination with POINT

BOSTON--(BUSINESS WIRE)--Therapeutics Acquisition Corp, d/b/a Research Alliance Corp. I, a Delaware corporation (“the Company”) (Nasdaq: RACA) announced today that its registration statement on Form S-4...

4 months ago - Business Wire

POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC

INDIANAPOLIS, June 04, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a global radiopharmaceutical company dedicated to successfully delivering precision radioligand therapy to cancer patients, ...

4 months ago - GlobeNewsWire

POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility

INDIANAPOLIS--(BUSINESS WIRE)--POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, announced today th...

4 months ago - Business Wire

Australis Capital completes first phase of Green Therapeutics acquisition with cannabis subsidiary purchase

Australis Capital Inc (CSE:AUSA) (OTC:AUSAF) (FRA:AC4) announced Wednesday that it has completed the first stage of its previously announced acquisition of Nevada cannabis company Green Therapeutics LLC...

6 months ago - Proactive Investors

Takeda To Expand Immuno-Oncology Portfolio With Maverick Therapeutics Acquisition

Takeda Pharmaceutical Co Ltd (NYSE: TAK) has exercised the option to acquire Maverick Therapeutics, following an agreement signed in 2017, in which Takeda received an equity stake and an exclusive right...

Other symbols:TAK
7 months ago - Benzinga

Why This Top Venture Capitalist Is Raising Money With a Biotech SPAC

These shell companies allow the businesses they acquire to go public much more quickly than an IPO would. Is it time to buy in?

Other symbols:INVAJAZZTBPHTXG
1 year ago - The Motley Fool

Why Some Biotech Companies Are Turning to SPACs

Forget traditional IPOs! This blank check vehicle is proving to be an effective tool for biotech companies to raise capital.

Other symbols:IMVTPHGE
1 year ago - The Motley Fool

Therapeutics Acquisition Corp., Sponsored by RA Capital Management, L.P.

BOSTON--(BUSINESS WIRE)--Therapeutics Acquisition Corp. (Nasdaq: TXAC) (the "Company") announced today that on July 10, 2020 it closed its initial public offering of 13,570,000 shares of Class A...

1 year ago - Business Wire

Therapeutics Acquisition Corp. Jumps 22% in IPO Debut

The special purpose acquisition company is sponsored by RA Capital Management.

1 year ago - The Motley Fool